Zidesamtinib drives 94 percent response in TKI-naïve, ROS1+ NSCLC

8 hours ago
Elvira Manzano
Elvira ManzanoSenior Managing Editor; MIMS
Elvira Manzano
Elvira Manzano Senior Managing Editor; MIMS
ARROS-1 investigator Dr Alexander DrilonARROS-1 investigator Dr Alexander Drilon

The ROS1-selective macrocyclic tyrosine kinase inhibitor (TKI) zidesamtinib demonstrates clinically meaningful activity in TKI-naïve patients with advanced ROS1 fusion-positive non-small cell lung cancer (ROS1+ NSCLC), as shown in the global phase I/II ARROS-1 trial, presented at WCLC 2026.

At a median follow-up of 15.2 months, the objective response rate (ORR) was 94 percent (88 of 94 efficacy-evaluable TKI-naïve patients), and the complete response rate (CRR) was 15 percent. The median duration of response (DOR) was not reached, with 96 percent, 94 percent, and 86 percent of patients maintaining their responses at 6, 9, and 12 months, respectively. [WCLC 2026, abstract PL03.06]

Similarly, the median progression-free survival (PFS) was not reached, with rates of 95 percent, 95 percent, and 90 percent at 6, 9, and 12 months, respectively.

“Zidesamtinib’s safety profile is consistent with previous reports, with low rates of dose reduction and discontinuation,” reported principal investigator Dr Alexander Drilon of Memorial Sloan Kettering Cancer Center and Weill Cornell Medical Center in New York, US, at WCLC 2026. “These findings support further investigation of zidesamtinib in earlier lines of therapy.”

Global first-in-human trial

Across all lines of therapy, 532 patients with ROS1+ NSCLC received zidesamtinib 100 mg once daily, including 183 who were TKI-naïve. The primary outcome was the ORR, assessed by blinded independent central review (BICR). The study population was geographically diverse, with 35 percent of patients enrolled in the Asia-Pacific region, 33 percent in Europe and 32 percent in North America.

At baseline, the median age in the TKI-naïve, ROS-1 population was 59 years; 59 percent were women, 59 percent were never smokers, and 17 percent had central nervous system (CNS) metastases. Ninety-three percent had stage IV disease, and 27 percent had received platinum-based chemotherapy and/or immunotherapy.

At WCLC 2026, Drilon presented results for the TKI-naïve efficacy population of 94 patients and safety data for all trial participants.

The CNS response-evaluable population of 10 patients comprised those with measurable baseline lesions, as assessed by BICR, and who had no radiation within 2 months of zidesamtinib initiation.

Despite the small number of patients evaluated, the CNS response findings were promising. “All 10 patients had an intracranial (IC) response to therapy, and seven of 10 had an intracranial complete response,” Drilon reported. “Additionally, no CNS progression events were observed in the 78 patients without baseline brain metastases.”

Finally, in the expanded safety population of 532 patients, the most common treatment-emergent adverse events (TEAEs) were peripheral oedema (42 percent), increased creatine phosphokinase (23 percent), constipation (23 percent), weight gain (22 per cent), and transaminitis (increased aspartate aminotransferase (AST), 15 percent; increased alanine aminotransferase (ALT), 18 percent). Overall, TEAEs led to dose reductions in 12 percent and discontinuations in 4 percent.

“Furthermore, we saw a lower frequency of neurological side effects relative to other ROS1-TKIs that are currently approved,” Drilon continued. “Finally, the dose reduction and dose discontinuation rates due to treatment-related adverse events were low at 11 percent and 1 percent, respectively.”

Trifecta of benefits

“I think we’ve seen the trifecta for zidesamtinib. We’ve seen early, strong efficacy, in fact, the highest we’ve seen in lung cancer, with an OR of 94 percent. We’ve also seen early durability, with only 10 percent progressing at 12 months,” said study discussant Dr Malinda Itchins of the Royal North Shore Hospital & Chris O’Brien Lifehouse in Sydney, Australia.

“We see a favourable tolerability profile, partly due to reduced TRK*-related neurological toxicity. We also observe CNS activity, which is important for avoiding whole-brain radiation and for preserving quality of life and function. I think the future is brighter for those living with, caring for, researching, and treating ROS1+ lung cancers,” she continued.

Newer selective ROS1 inhibitor

First-generation frontline TKIs for locally advanced or metastatic ROS1+ NSCLC have significant drawbacks, including limited central nervous system (CNS) activity and dose-limiting side effects, such as TRK-related neurotoxicities, including dizziness, ataxia, and dysgeusia.

“Zidesamtinib is a newer, selective ROS1 inhibitor designed to overcome these limitations by maximising ROS1 and mutant ROS1 activity and CNS penetration, while minimizing TRK inhibition,” said Drilon. “It also has broader activity against treatment-resistant ROS1 mutations, including G2032R.”

Earlier results from ARROS-1 demonstrated the efficacy of zidesamtinib in adults with previously treated locally advanced or metastatic ROS1+ NSCLC, leading to US FDA approval for this indication. [https://www.fda.gov/drugs/cancer-approvals/fda-approves-zidesamtinib-ros1-positive-non-small-cell-lung-cancer]

The new findings will support a planned supplemental new drug application to the US FDA for zidesamtinib use in the first-line setting.

 

*tropomyosin receptor kinase